Stephens Investment Management Group LLC Boosts Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Stephens Investment Management Group LLC increased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 1.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,932,209 shares of the specialty pharmaceutical company’s stock after purchasing an additional 33,710 shares during the quarter. Stephens Investment Management Group LLC owned 3.51% of Supernus Pharmaceuticals worth $60,246,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of SUPN. Sei Investments Co. boosted its holdings in shares of Supernus Pharmaceuticals by 24.4% during the 1st quarter. Sei Investments Co. now owns 330,580 shares of the specialty pharmaceutical company’s stock valued at $11,276,000 after acquiring an additional 64,752 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Supernus Pharmaceuticals by 205.2% in the first quarter. Russell Investments Group Ltd. now owns 97,988 shares of the specialty pharmaceutical company’s stock worth $3,342,000 after purchasing an additional 65,880 shares during the last quarter. Vanguard Group Inc. grew its position in Supernus Pharmaceuticals by 2.3% in the 4th quarter. Vanguard Group Inc. now owns 6,214,731 shares of the specialty pharmaceutical company’s stock worth $179,854,000 after purchasing an additional 142,551 shares during the period. State Board of Administration of Florida Retirement System raised its stake in Supernus Pharmaceuticals by 250.6% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 49,160 shares of the specialty pharmaceutical company’s stock valued at $1,781,000 after buying an additional 35,137 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Supernus Pharmaceuticals by 26.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company’s stock valued at $45,077,000 after buying an additional 351,900 shares during the period.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on SUPN. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock opened at $34.07 on Friday. Supernus Pharmaceuticals, Inc. has a 1 year low of $23.05 and a 1 year high of $35.56. The firm has a fifty day moving average price of $33.05 and a 200-day moving average price of $30.39. The company has a market cap of $1.88 billion, a price-to-earnings ratio of 378.56 and a beta of 0.88.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 EPS for the quarter, missing the consensus estimate of $0.39 by ($0.03). The company had revenue of $168.30 million during the quarter, compared to the consensus estimate of $148.83 million. Supernus Pharmaceuticals had a return on equity of 0.56% and a net margin of 0.83%. The firm’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same period last year, the business earned ($0.02) EPS. Equities research analysts expect that Supernus Pharmaceuticals, Inc. will post 1.53 EPS for the current year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.